Logo image of TLT.CA

THERALASE TECHNOLOGIES INC (TLT.CA) Stock Fundamental Analysis

Canada - TSX-V:TLT - CA88337V1004 - Common Stock

0.2 CAD
0 (0%)
Last: 10/21/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TLT. TLT was compared to 16 industry peers in the Health Care Equipment & Supplies industry. TLT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TLT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TLT had negative earnings in the past year.
In the past year TLT has reported a negative cash flow from operations.
TLT had negative earnings in each of the past 5 years.
TLT had a negative operating cash flow in each of the past 5 years.
TLT.CA Yearly Net Income VS EBIT VS OCF VS FCFTLT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -141.86%, TLT perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
TLT has a Return On Equity of -335.23%. This is in the better half of the industry: TLT outperforms 62.50% of its industry peers.
Industry RankSector Rank
ROA -141.86%
ROE -335.23%
ROIC N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
TLT.CA Yearly ROA, ROE, ROICTLT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

TLT has a Gross Margin (55.81%) which is comparable to the rest of the industry.
TLT's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
TLT.CA Yearly Profit, Operating, Gross MarginsTLT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLT has been increased compared to 1 year ago.
The number of shares outstanding for TLT has been increased compared to 5 years ago.
Compared to 1 year ago, TLT has an improved debt to assets ratio.
TLT.CA Yearly Shares OutstandingTLT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TLT.CA Yearly Total Debt VS Total AssetsTLT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -18.13, we must say that TLT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.13, TLT perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
A Debt/Equity ratio of 0.13 indicates that TLT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.13, TLT is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -18.13
ROIC/WACCN/A
WACC7.84%
TLT.CA Yearly LT Debt VS Equity VS FCFTLT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

TLT has a Current Ratio of 0.96. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
TLT's Current ratio of 0.96 is fine compared to the rest of the industry. TLT outperforms 68.75% of its industry peers.
TLT has a Quick Ratio of 0.96. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
TLT's Quick ratio of 0.62 is fine compared to the rest of the industry. TLT outperforms 68.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.62
TLT.CA Yearly Current Assets VS Current LiabilitesTLT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.27% over the past year.
The Revenue has grown by 16.00% in the past year. This is quite good.
TLT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.40% yearly.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)16%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%117.89%

3.2 Future

Based on estimates for the next years, TLT will show a very strong growth in Earnings Per Share. The EPS will grow by 37.61% on average per year.
Based on estimates for the next years, TLT will show a very strong growth in Revenue. The Revenue will grow by 256.32% on average per year.
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TLT.CA Yearly Revenue VS EstimatesTLT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
TLT.CA Yearly EPS VS EstimatesTLT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.01 -0.01 -0.02 -0.03 -0.04

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLT.CA Price Earnings VS Forward Price EarningsTLT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLT.CA Per share dataTLT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03

4.3 Compensation for Growth

TLT's earnings are expected to grow with 37.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.82%
EPS Next 3Y37.61%

More info and screens

0

5. Dividend

5.1 Amount

TLT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERALASE TECHNOLOGIES INC

TSX-V:TLT (10/21/2025, 7:00:00 PM)

0.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-26 2025-08-26/amc
Earnings (Next)11-25 2025-11-25
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap49.56M
Analysts84.44
Price Target0.71 (255%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.63%
Min EPS beat(2)-94.17%
Max EPS beat(2)2.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-24.53%
Min Revenue beat(2)-55.73%
Max Revenue beat(2)6.67%
Revenue beat(4)3
Avg Revenue beat(4)88.3%
Min Revenue beat(4)-55.73%
Max Revenue beat(4)236.89%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)50%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.4
P/FCF N/A
P/OCF N/A
P/B 38.82
P/tB 38.82
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.86%
ROE -335.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.81%
FCFM N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.64%
Cap/Sales 8.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.62
Altman-Z -18.13
F-Score4
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)14.29%
Cap/Depr(5y)27.96%
Cap/Sales(3y)3.87%
Cap/Sales(5y)8.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue 1Y (TTM)16%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%117.89%
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
EBIT growth 1Y2.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.52%
OCF growth 3YN/A
OCF growth 5YN/A